Monitor active

Research Monitor

Every night, a Claude agent queries PubMed for new papers on STRC, DFNB16, and inner ear gene therapy. It reads each abstract, scores relevance, and writes analysis of what it means for our program. Papers appear here automatically.

2 papers indexed Last scan: 2026-04-14 Runs daily 02:00 UTC

How it works

01 / Scan

PubMed queried for STRC, stereocilin, DFNB16, cochlear gene therapy, and related terms. New PMIDs since yesterday are collected.

02 / Analyze

Claude reads the abstract and full text when available. Scores relevance 1–10. Extracts what it means for mini-STRC, delivery, and regulatory path.

03 / Publish

Summaries committed to GitHub as Markdown. GitHub Actions builds and deploys here. Brain vault synced via symlink — appears in Obsidian the same morning.

7/10 FDA Path New

Gene Therapy for Infants and Children With Otoferlin-Related Auditory Neuropathy Spectrum Disorder

Lesperance et al. · Ear and Hearing

gene-therapyhearing-lossotoferlinotofauditory-neuropathyclinical-trialpediatricfda-pathway

What they found

This paper reviews the current state of otoferlin (OTOF) gene therapy for infants and children with auditory neuropathy spectrum disorder (ANSD). After decades of research on hair cell regeneration, otoferlin gene therapy has emerged as the first successful inner ear gene therapy, with early clinical results demonstrating hearing restoration. The authors discuss the clinical framework for treating pediatric patients and raise the critical question of whether this early success will translate to other forms of genetic hearing loss. The paper contextualizes otoferlin gene therapy within the broader landscape of hearing loss treatment.

How this applies to mini-STRC

This is highly relevant to our program: (1) Otoferlin gene therapy is the furthest-advanced hearing loss gene therapy and serves as the regulatory and clinical precedent for all subsequent inner ear gene therapies, including mini-STRC. (2) OTOF (~6kb CDS) is similarly oversized for a single AAV, and the dual-AAV approach used for otoferlin is an important reference — though our mini-gene strategy takes a different approach to the payload problem. (3) The clinical endpoints, outcome measures, and patient selection criteria established for OTOF trials will likely inform FDA expectations for STRC gene therapy. (4) The paper’s discussion of whether success with otoferlin will replicate in other forms of genetic HL directly frames the question our program must answer. (5) Understanding the pediatric clinical framework is essential since DFNB16 patients are typically identified in childhood.

Key numbers

  • Gene: OTOF (otoferlin) — ~6kb CDS, dual-AAV delivery approach
  • Target population: infants and children with ANSD
  • Status: early clinical success demonstrated, ongoing trials
PubMed ↗ DOI ↗
6/10 Applicable New

Postnatal Slc26a4 gene therapy improves hearing and structural integrity in a hereditary hearing loss model

Tsai et al. · The Journal of Clinical Investigation

gene-therapyhearing-lossaavslc26a4dfnb4cochleaendolymphatic-sactherapeutic-window

What they found

SLC26A4 mutations are the second most common cause of hereditary hearing loss in many Asian countries (DFNB4). The authors demonstrated that postnatal AAV-mediated Slc26a4 gene therapy can improve hearing and preserve structural integrity of the inner ear in an animal model. Critically, they identified a therapeutic window for intervention — establishing that timing of gene delivery matters for efficacy. The study targeted the endolymphatic sac and cochlear lateral wall, showing these are viable sites for effective gene therapy intervention in DFNB4.

How this applies to mini-STRC

This is directly informative for our mini-STRC program in several ways: (1) It demonstrates postnatal gene therapy feasibility for a different hereditary hearing loss gene, validating the general approach. (2) The identification of a critical therapeutic window is important — we should consider whether STRC/DFNB16 has a similar window where intervention must occur before irreversible hair cell damage. (3) Their targeting of specific cochlear structures (endolymphatic sac, lateral wall) contrasts with our need to target outer hair cells specifically, but the delivery methodology and surgical approach may be informative. (4) As another oversized-gene adjacent program (SLC26A4 is ~2.3kb CDS, fitting AAV), their regulatory/preclinical path provides a reference for DFNB16 IND strategy.

Key numbers

  • Gene: SLC26A4 (pendrin) — second most common cause of hereditary HL in Asian populations
  • Target structures: endolymphatic sac and cochlear lateral wall
  • Finding: critical therapeutic window identified for postnatal intervention
PubMed ↗ DOI ↗